Omicron SARS-CoV-2 outcomes in vaccinated individuals with heart failure and ischaemic heart disease
- PMID: 40471109
- DOI: 10.47102/annals-acadmedsg.202535
Omicron SARS-CoV-2 outcomes in vaccinated individuals with heart failure and ischaemic heart disease
Abstract
Introduction: Outcomes after SARS-CoV-2 Omicron infection in patients with heart failure (HF) and ischaemic heart disease (IHD) remain poorly defined.
Method: In a highly vaccinated cohort of adult Singapore citizens and permanent residents, we used Cox proportional hazards models (adjusted for sociodemographic variables and comorbidities) to compare the risks of Omicron infection, COVID-19- related hospitalisation, and severe COVID-19 between indivi-duals with HF or IHD and matched controls without these conditions.
Results: From national databases, we identified 15,426 HF patients matched 1:∼3 to 41,221 controls, and 110,442 IHD patients matched 1:∼2 to 223,843 controls. Over 80% of HF and IHD patients had received at least 3 vaccine doses. During the Omicron-predominant period, both HF and IHD cohorts demonstrated higher adjusted risks of COVID-19 hospitalisation compared with matched controls (HF: adjusted hazard ratio [aHR] 1.77, 95% confidence interval [CI] 1.65-1.90; IHD: aHR 1.21, 95% CI 1.17-1.26). Among those with at least 1 HF-or IHD-related admission in the prior year, hospitalisation risk was further elevated (HF: aHR 1.27, 95% CI 1.13-1.42; IHD: aHR 1.11, 95% CI 1.01-1.23). Receipt of ≥3 vaccine doses was associated with substantially lower risk of severe COVID-19 versus only 2 doses (HF: aHR 0.35, 95% CI 0.28-0.43; IHD: aHR 0.27, 95% CI 0.23-0.32). A fourth dose conferred additional reductions in infection and adverse outcomes, though CIs for infection overlapped with those for 3 doses.
Conclusion: During Omicron predominance, HF and IHD patients experienced greater risk of COVID-19 hospitalisation and severe COVID-19 versus matched controls. Booster vaccinations attenuated these risks. Individuals with recent HF/IHD admissions should be prioritised for receipt of booster vaccine doses.
Keywords: COVID-19; Omicron; SARS-CoV-2; boosters; cardiology; heart failure; infectious diseases; vaccination.
Conflict of interest statement
This work was not grant-funded. The authors declare they have no affiliations or financial involvement with any commercial organisation with a direct financial interest in the subject or materials discussed in the manuscript.
Similar articles
-
A Nationwide Cohort Study of Delta and Omicron SARS-CoV-2 Outcomes in Vaccinated Individuals With Chronic Lung Disease.Chest. 2024 Oct;166(4):685-696. doi: 10.1016/j.chest.2024.05.017. Epub 2024 Jun 11. Chest. 2024. PMID: 38871281
-
Autoimmune Sequelae After Delta or Omicron Variant SARS-CoV-2 Infection in a Highly Vaccinated Cohort.JAMA Netw Open. 2024 Aug 1;7(8):e2430983. doi: 10.1001/jamanetworkopen.2024.30983. JAMA Netw Open. 2024. PMID: 39212988 Free PMC article.
-
Risk factors for COVID-19 hospitalisation after booster vaccination during the Omicron period: A French nationwide cohort study.J Infect Public Health. 2024 Jul;17(7):102450. doi: 10.1016/j.jiph.2024.05.007. Epub 2024 May 14. J Infect Public Health. 2024. PMID: 38823086
-
Risk of death and cardiovascular events following COVID-19 vaccination or positive SARS-CoV-2 test amongst adult Singaporeans during omicron transmission.Vaccine. 2024 Dec 2;42(26):126356. doi: 10.1016/j.vaccine.2024.126356. Epub 2024 Sep 18. Vaccine. 2024. PMID: 39299002
-
Real-world evidence on the efficacy of bivalent booster doses of SARS-CoV-2 vaccine in respect of monovalent boosters or primary cycle of vaccination: a narrative review.Epidemiol Prev. 2023 Nov-Dec;47(6):331-343. doi: 10.19191/EP23.6.A626.081. Epidemiol Prev. 2023. PMID: 38314543 Review. English.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous